Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) is a publicly traded Healthcare sector company. As of July 26, 2026, QNTM trades at $2.99 with a market cap of $19.13M and a P/E ratio of 0.00. QNTM moved +2.82% today. Year to date, QNTM is -59.04%; over the trailing twelve months it is -87.45%. Its 52-week range spans $2.07 to $38.25. Rallies surfaces QNTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quantum BioPharma Details MS Candidate Mechanism, Preclinical Efficacy and Phase I Timeline: Quantum BioPharma executives outlined the mechanism of their lead MS candidate, highlighting remyelination activity and reporting preclinical lesion-load reductions of up to 55%. They also revealed plans for a 50-subject Phase I safety trial in Q3 2026, a $5 million private placement and U.S./EU licensing targets.
| Metric | Value |
|---|---|
| Price | $2.99 |
| Market Cap | $19.13M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $38.25 |
| 52-Week Low | $2.07 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
QNTM analyst coverage data. Average price target: $0.00.